This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

ONLINE REGISTRATION CLOSES IN:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Jake Galson, Ph.D.
Head of Technology at Alchemab Therapeutics

Profile

Dr. Galson is the Head of Technology at Alchemab Therapeutics. He oversees the development and usage of Alchemab's data-driven antibody and target discovery platform. Previously he was the Bioinformatics lead at Kymab Ltd, where his group developed the IntelliSelect® antibody discovery software platform. Dr. Galson is one of the pioneers of immune receptor repertoire sequencing, serving as a member of the AIRR community, and authoring numerous publications in the area. He has worked at The Oxford Vaccine Group, GSK Vaccines, and University of Zürich, applying this approach to further understand basic immunology, as well as in support of vaccine development, diagnostics, and antibody drug discovery. Dr. Galson holds a BA in Biological Sciences and a PhD in Medical Sciences, both from the University of Oxford.

Agenda Sessions

  • Mining Large Antibody Sequence Datasets for Therapeutic Antibody Discovery

    16:15